Huang lab applies a multidisciplinary approach to elucidate the mechanisms and functions of epigenetic modifications including methylation and acetylation to develop novel therapeutic agents for cancer, metabolic, infectious, and neurodegenerative diseases; rational designs and synthesize selective and potent inhibitors for methyltransferases and acetyltransferases; develop HTS assay and efficiently create compounded libraries to screen lead compounds.
Project 1: Targeting Methyltransferases (NTMTs, NNMT, and PRMTs) to discover new drugs
Strategies to build MTase bisubstrate analogs: PMID:32605369; PMID: 30883119; PMID:30883119;
Available MTase Inhibitors:
Protein n-terminal MTase 1/2 (NTMT1/2): DC541 (acs med chem letts); GD562; GD433 (pmid: 36634151)
Nicotinamide N-MTase (NNMT): LL320 (pmid: 31724854); II399 (pmid: 35134268); II559 and II802 (pmid: 37523719); II630; II679
Protein arginine methyltransferases (PRMTs): YD1342 (selective and potent PRMT4 inhibitor in cellular and animal models)
Project 2: Targeting Protein α-N-terminal Acetylation
Available Protein N-terminal acetyltransferase (NAT) inhibitors
NatD: YD612 (pmid:34110812)
Huang Lab is always open to collaborative opportunities. If you are interested, please contact Dr. Rong Huang at huang-r at purdue dot edu.